ESPR - Esperion Therapeutics, Inc.
ANN ARBOR, Mich., May 14, 2026 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that on May 12 2026, the Company granted 23 new employees 260,000 restricted stock units (RSUs) under Esperion's 2017 Inducement Equity Incentive Plan.
Esperion shares jump nearly 44% in a month. The primary catalyst was Archimed's agreement to acquire the company in a deal valued at up to $1.1 billion, including milestone payments.
– Presentations Examine Findings From the Pediatric Phase 2 Study, As Well As Factors Associated With Enhanced LDL-C Reductions in Adult Patients Enrolled in Clear Outcomes – – Pediatric Phase 2 Study Demonstrated Bempedoic Acid Treatment Reduced LDL-C in Children with Heterozygous Familial Hypercholesterolemia (HeFH) Congruent with Reductions in Adult Exposures – – New Analyses from CLEAR Outcomes Trial Identified Factors Associated With Enhanced LDL-C Reductions in Adult Patients – ANN ARBOR, Mich., May 13, 2026 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that two new abstracts and three encore abstracts have been accepted for presentation at the European Atherosclerosis Society (EAS) Congress 2026 taking place on May 24-27, 2026, in Athens, Greece.
NEW YORK, May 05, 2026 (GLOBE NEWSWIRE) -- Class Action Attorney Juan Monteverde with Monteverde & Associates PC (the “M&A Class Action Firm”), has recovered millions of dollars for shareholders and is recognized as a Top 50 Firm in the 2025 ISS Securities Class Action Services Report. We are headquartered at the Empire State Building in New York City and are investigating
NEW YORK CITY & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Esperion Therapeutics, Inc. (NasdaqGM: ESPR) to funds managed by ARCHIMED. Under the terms of the proposed transaction, shareholders of Esperion will receive $3.16 per share in cash and the right to participate in contingent milestone payments for each share of Esperion that they own. KSF is se.
NEW YORK, May 01, 2026 (GLOBE NEWSWIRE) -- Class Action Attorney Juan Monteverde with Monteverde & Associates PC (the “M&A Class Action Firm”), has recovered millions of dollars for shareholders and is recognized as a Top 50 Firm in the 2025 ISS Securities Class Action Services Report. The firm is headquartered at the Empire State Building in New York City and is investigating Esperion Therapeutics, Inc. (NASDAQ: ESPR ) related to its sale to funds managed by ARCHIMED. Under the terms of the proposed transaction, Esperion shareholders are expected to receive $3.16 per share in cash and the right to participate in contingent milestone payments. Is it a fair deal?
MILWAUKEE, May 1, 2026 /PRNewswire/ -- Ademi LLP is investigating Esperion (NASDAQ: ESPR) for possible breaches of fiduciary duty and other violations of law in its recently announced transaction with ARCHIMED. Click here to learn how to join our investigation and obtain additional information or contact us at [email protected] or toll-free: 866-264-3995.
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating the sale of Esperion Therapeutics, Inc. (NASDAQ: ESPR) to funds managed by ARCHIMED for $3.16 per share in cash and the right to participate in contingent milestone payments. Halper Sadeh encourages Esperion shareholders to click here to learn more about their rights and options or contact Daniel Sadeh or Zachary Halper free of charge at (212) 763-0060 or [email protected] or [email protected].
Investment firm Archimed will take Esperion Therapeutics private for up to $1.1 billion, the companies said on Friday, sending the drugmaker's shares up over 55% in premarket trading.
Esperion shareholders to receive $3.16 per share in cash at closing, plus the right to participate in up to $100 million in aggregate contingent milestone payments
Esperion shareholders to receive $3. 16 per share in cash at closing, plus the right to participate in up to $100 million in aggregate contingent milestone payments Represents total equity value of up to approximately $1. 1 billion ANN ARBOR, Mich. , May 01, 2026 (GLOBE NEWSWIRE) -- Esperion Therapeutics (Nasdaq: ESPR) ("Esperion," or the "Company"), a commercial-stage biopharmaceutical company dedicated to developing and delivering innovative cardiometabolic and rare/orphan disease therapies, and ARCHIMED ("ARCHIMED"), a leading investment firm focused exclusively on healthcare industries, today announced that they have entered into a definitive agreement under which funds managed by ARCHIMED will acquire Esperion in a transaction valued at up to approximately $1.
ANN ARBOR, Mich., April 23, 2026 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced it will report first quarter 2026 financial results before the market opens on Thursday, May 7, 2026.
Esperion Therapeutics (NASDAQ: ESPR) outlined its commercial progress and strategic priorities at Needham and Company's 25th Annual Healthcare Conference, highlighting revenue growth, new clinical and guideline tailwinds for its cholesterol franchise, and the recent acquisition of Corstasis Therapeutics and its heart failure product Enbumyst. President and CEO Sheldon Koenig said the company has made significant strides
Esperion Therapeutics (ESPR) reported earnings 30 days ago. What's next for the stock?
JPMorgan Chase and Co. raised its stake in Esperion Therapeutics, Inc. (NASDAQ: ESPR) by 68.4% in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 945,491 shares of the biopharmaceutical company's stock after buying an additional 384,095 shares during the
NEW YORK and ANN ARBOR, Mich., April 02, 2026 (GLOBE NEWSWIRE) -- Athyrium Capital Management, LP and Esperion Therapeutics, Inc. (Nasdaq: ESPR) today announced the entry into a $50 million royalty financing agreement under which certain funds managed by Athyrium Capital Management (the “Athyrium Funds”) will acquire 100% of Esperion's royalty interest, held by Esperion pursuant to that certain License and Collaboration Agreement, dated as of April 17, 2020, as amended, by and among Esperion and Otsuka Pharmaceutical Co., Ltd (“Otsuka”), of Otsuka's net sales of bempedoic acid products in Japan from and after January 1, 2026, together with related regulatory and commercial milestone payments, subject to a cap.
– Enbumyst, First and Only FDA-Approved Nasal Spray Loop Diuretic Now Integrated into Esperion's Cardiovascular Franchise, Anticipated to Drive Portfolio Expansion, Commercial Leverage, and Continued Revenue Growth –
Executives from Esperion Therapeutics (NASDAQ: ESPR) highlighted accelerating revenue growth, plans to expand its commercial footprint, and details of a pending acquisition during remarks at the Citizens Life Sciences Conference in Miami, coming a day after the company reported earnings. 2025 results and momentum entering 2026 Chief Executive Officer Sheldon Koenig said Esperion delivered what he
– Bempedoic Acid Receives Strongest Endorsement from AHA/ACC Multisociety Guideline for Patients with Statin Intolerance and in Primary and Secondary Prevention Patients with Severe Hypercholesterolemia –
Shares of Esperion Therapeutics, Inc. (NASDAQ: ESPR - Get Free Report) have been assigned an average recommendation of "Moderate Buy" from the eight analysts that are currently covering the stock, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation, five have issued a buy